Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...

Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.

A bunch of men have been talking about 'Ozempic penis' as a side-effect of the drug, but an expert has explained the truth ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...

A weight-loss doctor is warning patients not to rely on Wegovy as a cure for obesity, saying the newly available medication could be more harmful than helpful.

“This is the first major study to compare the effect of two common diabetes treatments — GLP-1 medicines and metformin — on dementia risk, using health records from more than 174,000 people. The ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.